Mikhail I. Shtivelband
Experienced in Protein C Deficiency

Dr. Mikhail I. Shtivelband

Hematology
695 S Dobson Rd, 
Chandler, AZ 
Accepting New Patients
Offers Telehealth
Experienced in Protein C Deficiency
695 S Dobson Rd, 
Chandler, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joining Ironwood Cancer & Research Centers in 2004, Dr. Shtivelband received his medical degree and PhD in Experimental Hematology in Russia. After Internal Medicine Residency, Dr. Shtivelband received fellowship training in Hematology and Medical Oncology at MD Anderson Cancer Center in Houston, where he stayed for an additional year to participate in experimental research. Treating patients with all kinds of malignancies and benign hematological problems, Dr. Shtivelband has particular interest in developing research programs to bring the newest advances in the field of Oncology and Hematology to our community. Dr. Shtivelband also heads the Ironwood Cancer & Research Center's research program. He is Board Certified in Internal Medicine, Hematology and Medical Oncology.

Dr. Shtivelband is rated as an Experienced provider by MediFind in the treatment of Protein C Deficiency. His top areas of expertise are Hemochromatosis, Non-Small Cell Lung Cancer (NSCLC), Plasmacytoma, and Lung Cancer.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in AZ
Board Certifications
Internal Medicine
Internal Medicine (Sub: Hematology)
Internal Medicine (Sub: Medical Oncology)
Hospital Affiliations
Dignity Health Mercy Gilbert Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Sunshine Health
  • EPO
  • HMO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 22 Less Insurance Carriers -

Locations

Ironwood Physicians, PC
695 S Dobson Rd, Chandler, AZ 85224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Enrollment Status: Terminated
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: MBG453, Azacitidine, Decitabine, INQOVI
Study Phase: Phase 2
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer
A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer
Enrollment Status: Completed
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drugs: LAG525, spartalizumab, carboplatin
Study Phase: Phase 2
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
Enrollment Status: Terminated
Publish Date: December 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Enrollment Status: Terminated
Publish Date: May 28, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

13 Total Publications

Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
Journal: Leukemia & lymphoma
Published: January 15, 2021
Similar Doctors
Advanced in Protein C Deficiency
Dr. Devinder P. Singh
Hematology Oncology | Hematology | Oncology
Advanced in Protein C Deficiency
Dr. Devinder P. Singh
Hematology Oncology | Hematology | Oncology

Honorhealth Ambulatory

10510 N 92nd St, 
Scottsdale, AZ 
 (13.3 miles away)
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients
Offers Telehealth

Devinder Singh is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Protein C Deficiency. His top areas of expertise are Waldenstrom Macroglobulinemia, Paget Disease of the Breast, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Large-Cell Immunoblastic Lymphoma. Dr. Singh is currently accepting new patients.

Advanced in Protein C Deficiency
Dr. Hollis E. Shaw
Hematology Oncology | Hematology | Oncology
Advanced in Protein C Deficiency
Dr. Hollis E. Shaw
Hematology Oncology | Hematology | Oncology
6335 E Main St, Suite C1, 
Mesa, AZ 
 (10.7 miles away)
480-668-7060
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Hollis Shaw is a Hematologist Oncology specialist and a Hematologist in Mesa, Arizona. Dr. Shaw is rated as an Advanced provider by MediFind in the treatment of Protein C Deficiency. His top areas of expertise are Polycythemia Vera, Protein C Deficiency, Protein S Deficiency, and Congenital Antithrombin 3 Deficiency. Dr. Shaw is currently accepting new patients.

Advanced in Protein C Deficiency
Dr. Amikar Sehdev
Hematology Oncology | Hematology | Oncology
Advanced in Protein C Deficiency
Dr. Amikar Sehdev
Hematology Oncology | Hematology | Oncology

Ironwood Physicians PC

5810 W Beverly Lane, 
Glendale, AZ 
 (24.5 miles away)
623-312-3000
Languages Spoken:
English, Hindi, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Amikar Sehdev is a Hematologist Oncology specialist and a Hematologist in Glendale, Arizona. Dr. Sehdev is rated as a Distinguished provider by MediFind in the treatment of Protein C Deficiency. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Colorectal Cancer, and Melanoma. Dr. Sehdev is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shtivelband's expertise for a condition
ConditionClose
    View All 17 Distinguished Conditions
    View All 34 Advanced Conditions
    View All 132 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile